"Behavior and Basal Ganglia" Research Unit (EA 4712), University of Rennes 1, Rennes, France; Department of Neurology, Rennes University Hospital, Rennes, France.
"Behavior and Basal Ganglia" Research Unit (EA 4712), University of Rennes 1, Rennes, France; Department of Neurology, Rennes University Hospital, Rennes, France.
J Neurol Sci. 2018 Dec 15;395:113-118. doi: 10.1016/j.jns.2018.10.010. Epub 2018 Oct 7.
Treatment optimization using continuous subcutaneous apomorphine infusion (CSAI) improves the control of motor fluctuations of patients with Parkinson's disease (PD). Although CSAI seems to be cognitively and behaviorally safe and to improve the quality of life, very few studies have investigated its influence in these domains, especially in patients without cognitive impairment.
We estimated the impact of CSAI on motor symptoms, cognition, psychiatric domains and quality of life in parkinsonian patients without cognitive impairment by comparing the scores of 22 patients assessed before and 6 months after the start of add-on CSAI.
Optimized treatment with CSAI was associated with i) reduced motor fluctuations, ii) unchanged cognition, iii) unchanged psychiatric domains, and iv) improved quality of life in physical and psychological aspects.
In PD patients without cognitive impairment, CSAI improves motor symptoms and quality of life and, as suggested by previous studies, alters neither cognition nor mental health.
使用持续皮下阿朴吗啡输注（CSAI）进行治疗优化可改善帕金森病（PD）患者运动波动的控制。尽管 CSAI 在认知和行为上似乎是安全的，并能提高生活质量，但很少有研究调查其在这些领域的影响，尤其是在没有认知障碍的患者中。
我们通过比较 22 例患者在开始添加 CSAI 前和 6 个月后的评分，来评估 CSAI 对无认知障碍的帕金森病患者的运动症状、认知、精神领域和生活质量的影响。
CSAI 的优化治疗与 i）减少运动波动，ii）认知无变化，iii）精神领域无变化，以及 iv）改善身体和心理方面的生活质量有关。
在无认知障碍的 PD 患者中，CSAI 可改善运动症状和生活质量，且与先前的研究结果一致，既不会改变认知，也不会影响心理健康。
